Regulators yank former Lilly drug from market

A Parkinson’s disease medication originally developed and sold by Eli Lilly and Co. has been voluntarily pulled from the U.S. market after the Food and Drug Administration reviewed new information that associates it with heart problems.

Pergolide, which Lilly sold under the Permax brand, has been licensed to the Aliso Viejo, Calif., drugmaker Valeant Pharmaceuticals International, according to Bloomberg.

The FDA concluded alternative medications called dopamine agonists are safer. The newer drugs are Mirapex, sold by Boehringer Ingelheim GmbH, and Requip, sold by GlaxoSmithKline Plc.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}